Compare Humana Inc (HUM) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs VF Corp — how do they compare? Humana Inc trades at $405.62 (market cap $47.81B), while VF Corp trades at $16.85 (market cap $6.62B). The key difference: Humana Inc is far larger — about 7.2× VF Corp's market cap, and VF Corp pays the higher dividend (2.13%). Which is the better fit depends on your goals.
| HUM | VFC | |
|---|---|---|
Market Cap | $47.81B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $21.55 |
52-Week Low | $163.67 | $11.66 |
Enterprise Value | $56.85B | $10.77B |
Dividend Yield | 0.89% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
VFC trades at $16.78, down 1.18% on the day, with technical indicators showing a neutral to bearish short-term bias. The company reported mixed quarterly results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with revenue declining to $9.50 billion in 2025. Analyst sentiment is cautiously optimistic with a consensus price target of $19.33, while recent news highlights ongoing brand challenges and debt reduction efforts.
The outlook for VFC hinges on execution of its turnaround strategy, particularly revitalizing the Vans brand. Near-term catalysts include Q2 2026 earnings and continued debt management, but risks remain from weak consumer spending and competitive pressures. The stock offers potential upside to analyst targets if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
